The global gene editing market is projected to reach USD 8.49 billion by 2031, up from USD 5.23 billion in 2026, at a CAGR of 10.1%. The market is driven by technological advancements in CRISPR-based gene editing, increasing investments in genetic research, rising adoption of precision medicine, and the growing application of gene editing in drug discovery and development. In parallel, rising demand for genetically engineered cell lines, expanding research on cell and gene therapies, and advances in base and prime editing technologies are expected to further support market expansion.
The global gene editing market is characterized by the presence of established life science and biotechnology companies, including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), GenScript Biotech Corporation (China), Danaher Corporation (US), and Agilent Technologies, Inc. (US), among others. These companies compete through comprehensive gene editing reagent portfolios, advanced CRISPR technologies, product innovation, and strategic collaborations. Other prominent participants, including Revvity, Inc. (US), Lonza Group AG (Switzerland), Takara Bio Inc. (Japan), and REPROCELL Incorporated (Japan), are strengthening their positions through investments in genome engineering solutions, cell line development, and specialized gene editing services. Continued innovation in gene editing technologies, delivery systems, and high-throughput screening platforms is expected to shape the competitive landscape over the forecast period.
To know about the assumptions considered for the study download the pdf brochure
Thermo Fisher Scientific Inc. (US)
Thermo Fisher Scientific is a leading provider of gene editing reagents, kits, instruments, and molecular biology solutions. Its portfolio includes GeneArt CRISPR-Cas9 products, genome editing detection kits, guide RNA synthesis solutions, and associated transfection reagents for targeted genetic modification. The company supports applications in gene knockout, knock-in, cell line engineering, drug discovery, and functional genomics. Its extensive product portfolio, established laboratory technologies, and integrated gene editing workflows strengthen its position in the gene editing market.
Merck KGaA (Germany)
Merck KGaA is a leading supplier of gene editing products, including CRISPR-Cas9 reagents, synthetic guide RNAs, nucleases, and genome engineering solutions. Its portfolio includes SygRNA synthetic guide RNAs, Cas9 proteins, and associated reagents supporting targeted genetic modifications. These products enable applications in functional genomics, gene knockout, gene knock-in, disease modeling, and drug discovery. The company's established presence in molecular biology reagents, extensive research product portfolio, and genome editing technologies support its participation in the gene editing market.
GenScript Biotech Corporation (China)
GenScript is a major participant in the gene editing market, offering CRISPR reagents, gene synthesis solutions, and customized genome engineering services. Its portfolio includes GenCRISPR Cas9 nucleases, Cas12a proteins, guide RNA synthesis solutions, donor DNA templates, and related gene editing reagents. These products support targeted genome modification, cell line engineering, functional genomic research, and therapeutic development. The company's integrated research solutions, established gene synthesis capabilities, and expanding portfolio of genome editing products and services strengthen its competitive position in the market.
Agilent Technologies, Inc. (US)
Agilent Technologies is a leading provider of gene editing reagents, nucleic acid synthesis solutions, and genome engineering technologies. Its portfolio includes SureGuide chemically synthesized single-guide RNAs (sgRNAs), SurePrint oligonucleotide libraries, CRISPR-Cas9-related products, and associated design tools for targeted genetic modification. The company supports applications in gene knockout, knock-in, cell line engineering, functional genomics, and therapeutic development. Its advanced oligonucleotide synthesis capabilities, customizable guide RNA solutions, and established laboratory technologies strengthen its position in the gene editing market.
Market Ranking
The global gene editing market is characterized by the presence of established life science and biotechnology companies, including Thermo Fisher Scientific, Merck KGaA, GenScript, Agilent Technologies, and Revvity. Based on the company-level revenue estimates provided, Thermo Fisher Scientific holds a leading position, supported by its extensive gene editing reagents and kits portfolio, broad research customer base, and integrated laboratory solutions. Competitive differentiation increasingly depends on editing efficiency, targeting specificity, product innovation, technology integration, and the ability to support advanced research and therapeutic development applications.
Thermo Fisher Scientific Inc. (US) maintains a strong position through its GeneArt CRISPR-Cas9 products, gene editing detection kits, and supporting molecular biology reagents. Merck KGaA (Germany) offers CRISPR reagents, synthetic guide RNAs, and genome engineering solutions for research applications. GenScript Biotech Corporation (China) competes through its GenCRISPR product portfolio, custom nucleic acid synthesis capabilities, and specialized gene editing services. Danaher Corporation (US), through Integrated DNA Technologies, supports genome editing research with Alt-R CRISPR systems, guide RNAs, Cas nucleases, and donor DNA solutions.
Other prominent participants include Agilent Technologies (US), Revvity, Inc. (US), Lonza Group AG (Switzerland), Takara Bio Inc. (Japan), REPROCELL Incorporated (Japan), and Sangamo Therapeutics, Inc. (US). These companies participate through specialized gene editing reagents, CRISPR screening technologies, nucleic acid synthesis, cell-engineering solutions, and research services. Agilent offers SureGuide synthetic guide RNAs, while Revvity provides Dharmacon CRISPR and RNAi reagents, screening libraries, and base editing solutions. The remaining market includes specialized reagent manufacturers, genome engineering service providers, and emerging technology developers that compete through product innovation, customized research solutions, and collaborations with pharmaceutical companies and research institutes.
Related Reports:
Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Service (Vector, Library Construction, Screening), Technique (Knock-Out), Technology (CRISPR, ZFN, RNAi, TALEN), Application, End User, Region, Competition - Global Forecast to 2031
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE